130.50
Illumina Inc stock is traded at $130.50, with a volume of 1.17M.
It is down -1.12% in the last 24 hours and up +4.96% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$131.98
Open:
$133.22
24h Volume:
1.17M
Relative Volume:
0.61
Market Cap:
$19.82B
Revenue:
$4.34B
Net Income/Loss:
$850.00M
P/E Ratio:
23.89
EPS:
5.4635
Net Cash Flow:
$921.00M
1W Performance:
-1.33%
1M Performance:
+4.96%
6M Performance:
+34.22%
1Y Performance:
+75.52%
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ILMN
Illumina Inc
|
130.50 | 20.05B | 4.34B | 850.00M | 921.00M | 5.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
513.98 | 194.94B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
184.04 | 137.69B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
578.35 | 45.19B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
120.47 | 34.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
334.38 | 32.91B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
DNA Extraction, Isolation and Purification Market: Key Players - openPR.com
Gene Expression Analysis Market Set for Robust Growth to USD - openPR.com
Illumina Inc. (ILMN) – Pediatric Genomics Collaboration Bolsters Long-Term Growth Narrative Amid Mixed Historical ReturnsFast Rising Picks - Xã Châu Thành
Illumina Inc. (ILMN) Launches DRAGEN v4.5 Bioinformatics Suite, Expanding Addressable Market in Genomic Research and Clinical OncologyPost Announcement - Xã Thanh Hà
CSR News Feed | Explore the latest corporate social responsibility news from Illumina - Illumina
South America Next Generation Sequencing eDNA Biomonitoring - openPR.com
Metagenomics Market Key Companies AnalysisMerck KGaA, Thermo - openPR.com
Pharmacogenomics Market Leading Companies | F. Hoffmann-la - openPR.com
Metafoodx to Showcase Award-Winning AI Kitchen Intelligence Platform at the 2026 National Restaurant Association Show - GlobeNewswire Inc.
Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch
Tsinghua University brings hands-on multiomics training to young scientists - Illumina
UPS, Netflix, BlackRock And A Health Care Stock On CNBC's 'Final Trades'BlackRock (NYSE:BLK), Illumina - Benzinga
Illumina, Inc. Common Stock Ex-distribution When-Issued (ILMNV) - Minichart
Behavioral Patterns of ILMN and Institutional Flows - Stock Traders Daily
Illumina, Inc. $ILMN Shares Acquired by Cwm LLC - MarketBeat
Illumina Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Illumina (ILMN), Labcorp (LH) expand precision oncology NGS collaboration - MSN
ILMN Stock Price, Quote & Chart | ILLUMINA INC (NASDAQ:ILMN) - ChartMill
DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows - PR Newswire
Robeco Institutional Asset Management B.V. Trims Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Illumina Inc. stock (US4523271090): Why does its genomics dominance matter more now for U.S. investo - AD HOC NEWS
Illumina’s Pediatric Genomics Push Tests Long Term Growth Narrative - Yahoo Finance
Illumina partners with D3b on pediatric genomic data initiative By Investing.com - Investing.com Canada
How Investors Are Reacting To Illumina (ILMN) Board Turnover And Expanded Labcorp Precision Oncology Partnership - simplywall.st
Illumina partners with D3b on pediatric genomic data initiative - Investing.com
Illumina Partners with D3b to Advance Pediatric Cancer Research - Intellectia AI
100,000 child genomes power rare disease and cancer research - Stock Titan
Third View Private Wealth LLC Buys Shares of Illumina, Inc. - National Today
Third View Private Wealth LLC Buys Shares of 16,207 Illumina, Inc. $ILMN - MarketBeat
Massachusetts Financial Services Co. MA Invests $73.53 Million in Illumina, Inc. $ILMN - MarketBeat
Hardman Johnston Trims Illumina Stake - National Today
Illumina, Inc. $ILMN Shares Sold by Hardman Johnston Global Advisors LLC - MarketBeat
Illumina, Inc. $ILMN Holdings Decreased by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Baillie Gifford & Co. Reduces Position in Illumina, Inc. $ILMN - MarketBeat
ILMN Q4 2025 Earnings: Illumina Inc. beats EPS views, no revenue reportedCommunity Pattern Alerts - Xã Thanh Hà
Bioinformatics Market 2026- 2033 Overview: Share, Size, Value, - openPR.com
Illumina (ILMN), Labcorp (LH) Expand Precision Oncology NGS Collaboration - Insider Monkey
Epigenetics Market to Grow from US$ 2.06 Billion in 2024 to US$ - openPR.com
Illumina Inc. stock (US4523271090): Is its genomics leadership strong enough for long-term U.S. inve - AD HOC NEWS
Is It Time To Reassess Illumina (ILMN) After Its 61.7% One Year Share Price Rebound - Yahoo Finance
Is Illumina Stock Undervalued at $121? - TIKR.com
Illumina Inc stock (US4523271090): Is its genomics dominance strong enough to unlock new upside? - AD HOC NEWS
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - GlobeNewswire Inc.
Illumina Stock: Competitive Threats Priced In (NASDAQ:ILMN) - Seeking Alpha
Illumina Inc (ILMN) Stock Down 3.4% -- Now Undervalued? GF Score: 83/100 - GuruFocus
Informatics advances reveal the TruPath™ Genome towards comprehensive genomic insights - Illumina
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):